Comparison of the efficacy and safety of ziprasidone and risperidone in the treatment of schizophrenia

Objective To investigate the clinical efficacy and safety of ziprasidone and risperidone in the treatment of schizophrenia. Methods According to the digital table,64 patients with schizophrenia were randomly divided into the two groups, 32 cases in each group. The control group was given risperidone for treatment, while the observation group was given ziprasidone for treatment. The clinical efficacy was assessed by using the positive and negative symptom scale(PANSS), and adverse events were observed. Results The total effective rates of the control group and the observation group were 84.38% and 87.50%, there was no significant difference between the two groups(χ2= 2.66,P> 0.05); The PANSS score and each factor score of the two groups after treatment decreased significantly than before treatment(t= 8.11,7.86,7.72,7.90,6.77,6.58,7.52,7.40,all P 0.05); The incidence rate of adverse reaction of the observation group was 18.75%, which was significantly lower than 40.63% of the control group(χ2= 8.66,P< 0.05). Conclusion Ziprasidone has therapeutic equivalence with risperidone in the treatment of schizophrenia, with less adverse reaction, high security, it has good clinical application value. Key words: Schizophrenia; Ziprasidone; Risperidone